An Optimized Checkerboard Method for Phage-Antibiotic Synergy Detection

Viruses. 2022 Jul 14;14(7):1542. doi: 10.3390/v14071542.

Abstract

Phage-antibiotic synergy is a promising therapeutic strategy, but there is no reliable method for synergism estimation. Although the time-kill curve assay is a gold standard, the method is not appropriate for fast and extensive screening of the synergy. The aim is to optimize the checkerboard method to determine phage-chemical agent interactions, to check its applicability by the time-kill curve method, and to examine whether the synergy can be obtained with both simultaneous and successive applications of these agents. In addition, the aim is to determine interactions of the Pseudomonas phage JG024 with ciprofloxacin, gentamicin, or ceftriaxone, as well as the Staphylococcus phage MSA6 and SES43300 with ciprofloxacin, gentamicin, and oxacillin. The results show that the optimized checkerboard method is reliable and that results correspond to those obtained by the time-kill curve. The synergy is detected with the phage JG024 and ciprofloxacin or ceftriaxone against Pseudomonas aeruginosa, and the phage SES43300 with ciprofloxacin against MRSA. The synergy was obtained after simultaneous applications, and in the case of P. aeruginosa, after application of the second agent with delay of one hour, indicating that simultaneous application is the best mode of synergy exploitation for therapy. The checkerboard method can be used for thorough clinical studies on synergy and in the future for personalized therapy when infections are caused by multiple resistant bacteria.

Keywords: checkerboard method; phage-antibiotic synergy; time-kill curve.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Bacteriophages*
  • Ceftriaxone*
  • Ciprofloxacin / pharmacology
  • Drug Synergism
  • Gentamicins
  • Microbial Sensitivity Tests
  • Pseudomonas aeruginosa

Substances

  • Anti-Bacterial Agents
  • Gentamicins
  • Ciprofloxacin
  • Ceftriaxone

Grants and funding

This research was supported by the Science Fund of the Republic of Serbia, PROMIS, grant number 6066764, PHANTER.